OLIGOPHORE Trademark

Trademark Overview


On Wednesday, June 2, 2021, a trademark application was filed for OLIGOPHORE with the United States Patent and Trademark Office. The USPTO has given the OLIGOPHORE trademark a serial number of 90750400. The federal status of this trademark filing is ABANDONED - FAILURE TO RESPOND OR LATE RESPONSE as of Monday, April 17, 2023. This trademark is owned by Otolanum AG. The OLIGOPHORE trademark is filed in the Pharmaceutical Products and Computer & Software Services & Scientific Services categories with the following description:

Pharmaceutical preparations, namely, therapeutics comprising nucleic acids, peptides or proteins for use in the intracellular treatment or prevention of allergy, autoimmune, cardiovascular, dermatologic, endocrine, gastroenterological, hematologic, immunologic, infectious, metabolic, neurological, oncologic, ophthalmologic, otic, orthopedic, pain, pulmonary, psychiatric, mental health, respiratory, rheumatologic, urologic, and women's health diseases and disorders; Pharmaceutical preparations, namely, vaccines comprising nucleic acids, peptides or proteins for use in the intracellular treatment or prevention of diseases or disorders

Scientific research in the fields of therapeutics or vaccines comprising nucleic acids, peptides or proteins for use in the intracellular treatment or prevention of diseases or disorders
oligophore

General Information


Serial Number90750400
Word MarkOLIGOPHORE
Filing DateWednesday, June 2, 2021
Status602 - ABANDONED - FAILURE TO RESPOND OR LATE RESPONSE
Status DateMonday, April 17, 2023
Registration Number0000000
Registration DateNOT AVAILABLE
Mark Drawing4000 - Illustration: Drawing with word(s) / letter(s) / number(s) in Block form
Published for Opposition DateNOT AVAILABLE

Trademark Statements


Goods and ServicesPharmaceutical preparations, namely, therapeutics comprising nucleic acids, peptides or proteins for use in the intracellular treatment or prevention of allergy, autoimmune, cardiovascular, dermatologic, endocrine, gastroenterological, hematologic, immunologic, infectious, metabolic, neurological, oncologic, ophthalmologic, otic, orthopedic, pain, pulmonary, psychiatric, mental health, respiratory, rheumatologic, urologic, and women's health diseases and disorders; Pharmaceutical preparations, namely, vaccines comprising nucleic acids, peptides or proteins for use in the intracellular treatment or prevention of diseases or disorders
Goods and ServicesScientific research in the fields of therapeutics or vaccines comprising nucleic acids, peptides or proteins for use in the intracellular treatment or prevention of diseases or disorders

Classification Information


International Class005 - Pharmaceutical and veterinary preparations; sanitary preparations for medical purposes; dietetic substances adapted for medical use, food for babies; plasters, materials for dressings; material for stopping teeth, dental wax; disinfectants; preparations for destroying vermin; fungicides, herbicides.
US Class Codes005, 006, 018, 044, 046, 051, 052
Class Status Code6 - Active
Class Status DateThursday, August 26, 2021
Primary Code005
First Use Anywhere DateNOT AVAILABLE
First Use In Commerce DateNOT AVAILABLE

International Class042 - Scientific and technological services and research and design relating thereto; industrial analysis and research services; design and development of computer hardware and software.
US Class Codes100, 101
Class Status Code6 - Active
Class Status DateThursday, August 26, 2021
Primary Code042
First Use Anywhere DateNOT AVAILABLE
First Use In Commerce DateNOT AVAILABLE

Trademark Owner History


Party NameOtolanum AG
Party Type10 - Original Applicant
Legal Entity Type99 - Other
AddressZug 6300
CH

Trademark Events


Event DateEvent Description
Monday, April 17, 2023ABANDONMENT NOTICE E-MAILED - FAILURE TO RESPOND
Monday, April 17, 2023ABANDONMENT NOTICE MAILED - FAILURE TO RESPOND
Monday, April 17, 2023ABANDONMENT - FAILURE TO RESPOND OR LATE RESPONSE
Saturday, October 1, 2022NOTIFICATION OF FINAL REFUSAL EMAILED
Saturday, October 1, 2022FINAL REFUSAL E-MAILED
Saturday, October 1, 2022FINAL REFUSAL WRITTEN
Thursday, August 18, 2022TEAS/EMAIL CORRESPONDENCE ENTERED
Thursday, August 18, 2022CORRESPONDENCE RECEIVED IN LAW OFFICE
Thursday, August 18, 2022TEAS RESPONSE TO OFFICE ACTION RECEIVED
Friday, February 18, 2022NOTIFICATION OF NON-FINAL ACTION E-MAILED
Friday, February 18, 2022NON-FINAL ACTION E-MAILED
Friday, February 18, 2022NON-FINAL ACTION WRITTEN
Thursday, February 10, 2022ASSIGNED TO EXAMINER
Thursday, August 26, 2021NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
Saturday, June 5, 2021NEW APPLICATION ENTERED